Lazard Asset Management
AZN icon

Lazard Asset Management’s AstraZeneca AZN Stock Holding History

Lazard Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438M Buy
2,332,566
+115,679
+5% +$21.8M 0.66% 28
2026
Q1 		$433M Buy
2,216,887
+1,548,279
+232% +$299M 0.71% 27
2025
Q4 		$123M Buy
668,608
+1,328
+0.2% +$233K 0.21% 111
2025
Q3 		$102M Buy
667,280
+103,825
+18% +$15.7M 0.14% 137
2025
Q2 		$78.7M Sell
563,455
-892
-0.2% -$125K 0.11% 160
2025
Q1 		$83M Buy
564,347
+105,014
+23% +$15.2M 0.13% 134
2024
Q4 		$60.2M Sell
459,333
-121,102
-21% -$17M 0.09% 172
2024
Q3 		$90.4M Sell
580,435
-379,883
-40% -$61.3M 0.12% 131
2024
Q2 		$150M Buy
960,318
+718,952
+298% +$108M 0.19% 104
2024
Q1 		$32.7M Buy
241,366
+64,308
+36% +$8.52M 0.04% 291
2023
Q4 		$23.8M Buy
177,058
+35,278
+25% +$4.59M 0.03% 351
2023
Q3 		$19.2M Buy
141,780
+62,257
+78% +$8.5M 0.03% 389
2023
Q2 		$11.4M Buy
79,523
+24,954
+46% +$3.67M 0.01% 532
2023
Q1 		$7.57M Buy
54,569
+52,638
+2,726% +$7.08M 0.01% 648
2022
Q4 		$260K Buy
1,931
+247
+15% +$31K ﹤0.01% 1250
2022
Q3 		$183K Hold
1,684
– – ﹤0.01% 1288
2022
Q2 		$221K Sell
1,684
-182
-10% -$23.9K ﹤0.01% 1256
2022
Q1 		$246K Sell
1,866
-26,967
-94% -$3.23M ﹤0.01% 1220
2021
Q4 		$3.36M Sell
28,833
-377,559
-93% -$44.4M ﹤0.01% 850
2021
Q3 		$48.8M Buy
406,392
+318,288
+361% +$37.1M 0.06% 287
2021
Q2 		$10.6M Buy
+88,104
New +$9.67M 0.01% 590
2016
Q3 		– Sell
-182
Closed -$10K – 986
2016
Q2 		$10K Buy
+182
New +$10.6K ﹤0.01% 954
2016
Q1 		– Sell
-15
Closed -$1K – 1037
2015
Q4 		$1K Buy
+15
New +$983 ﹤0.01% 1069
2013
Q3 		– Sell
-59
Closed -$2K – 956
2013
Q2 		$2K Buy
+59
New +$3K ﹤0.01% 1007

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lazard Asset Management's AZN Position: Q2 2026 in Review

Lazard Asset Management increased its AstraZeneca (AZN) stake by 5.2% in Q2 2026, buying an estimated $21.8M and bringing the position to 2,332,566 shares worth $438M. The position accounts for 0.66% of the portfolio, ranked #28.

Lazard Asset Management first reported a position in AZN in Q2 2013 and has held it in 24 quarters since. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Lazard Asset Management held 2,332,566 shares of AstraZeneca worth $438M as of Q2 2026.
  • Lazard Asset Management bought 115,679 AstraZeneca shares in Q2 2026, an estimated $21.8M.
  • AstraZeneca made up 0.66% of Lazard Asset Management's portfolio in Q2 2026, its #28 holding.
  • Lazard Asset Management first reported a position in AstraZeneca in Q2 2013 and has held it in 24 quarters since.
  • 1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.